Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a light box help Parkinson's patients sleep better?

NCT ID NCT04291014

Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested different doses of light therapy to see which works best for improving sleep in people with Parkinson's disease. 203 participants used either bright-white or dim-red light boxes at different times of day. The goal was to find the most effective dose to ease sleep problems and fatigue.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SunRay light boxes (light therapy device)
What this could lead to
If it works, this could point toward a simple, non-drug way to improve sleep and reduce fatigue in Parkinson's disease.
What could go wrong
This is a completed dose-finding study, not a proof of effectiveness. The results may not show clear benefit, and light therapy might not work for everyone or could be inconvenient to use daily.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

203 people

The number who actually took part.

Started

Sep 2020

Finished

Jan 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of idiopathic PD as defined by the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease; 2. PD Hoehn and Yahr stage 2-4; 3. A score of 2 (mild) or above on the Sleep Problems question of the MDS-UPDRS Part 1; 4. Stable dose of all PD medications for at least 30 days prior to randomization; 5. Willingness to wear an Actiwatch and complete daily sleep logs; 6. Age 45 or above Exclusion Criteria: 1. Atypical or secondary forms of parkinsonism; 2. Co-existent significant sleep apnea at screening, as determined by the PI's clinical assessment; adequately treated sleep apnea, as assessed by sleep apnea machine download (CPAP download) will be permitted; 3. Co-existent symptomatic restless legs syndrome (RLS) (as assessed by the International Classification of Sleep Disorders (ICDS) diagnostic criteria for RLS) at screening; 4. Cognitive impairment as determined by a Mini Mental State Examination score \<25 at screening; 5. Presence of moderate depression defined as a Beck Depression Inventory II (BDI-II) score ≥20 at screening; 6. Current untreated hallucinations or psychosis (drug-induced or spontaneous) with a score of 2 or above on the Hallucinations and Psychosis question of the MDS-UPDRS Part 2; 7. Use of hypno-sedative drugs for sleep or stimulants, unless the participant has been on a stable dose for at least 60 days prior to the screening; 8. Ongoing or recent (within 30 days prior to screening) Cognitive Behavioral Therapy for Insomnia; 9. Use of antidepressants, unless the participant has been on a stable dose for at least 60 days prior to the screening; 10. Work hours between 10 PM and 6 AM, within 60 days prior to randomization or anticipated during the 16 weeks after screening; 11. Travel between 3 or more time zones within 45 days prior to study screening or anticipated such travel during the 16 weeks after screening; 12. Unstable or serious medical illness; 13. History of significant eye trauma or disease, retinopathy, or cataract Grade 4 that would significantly affect transmission or processing of light through either eye; 14. Current use, use at any time during study participation, or use within the 30 days prior to screening of photosensitizing or other medications that in the opinion of the investigator would interfere with the safety of the participant during the trial, including: amiodarone, porfimer, psoralens, chlorpromazine, quinidine, demeclocycline, temoporfin, tetracycline, fleroxacin, oral isoretinoin, voriconazole, nalidixic acid, thioridazine, St. John's wort, ofloxacin, and piroxicam; 15. Pregnant women will be excluded from participation; if a participant is pre-menopausal, a urine pregnancy test will be conducted at randomization to determine eligibility.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatigue are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fatigue Parkinson disease sleep disorder sleep-wake disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fatigue Parkinson disease Sleep disorder

Contacts and locations

Locations

  • Barrow Neurological Institute

    Phoenix, Arizona, 85013, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mount Sinai - Icahn School of Medicine

    New York, New York, 10029, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Ohio State University

    Columbus, Ohio, 43221, United States

  • SUNY Stonybrook

    Stony Brook, New York, 11794, United States

  • SUNY Upstate

    Syracuse, New York, 13210, United States

  • UC Davis

    Sacramento, California, 95817, United States

  • UC Irvine

    Irvine, California, 92697, United States

  • University of Alabama

    Birmingham, Alabama, 35233, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45219, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19107, United States

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Rochester

    Rochester, New York, 14642, United States

  • University of Utah

    Salt Lake City, Utah, 84132, United States

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

  • Vanderbilt University

    Nashville, Tennessee, 37232, United States

  • Wake Forest University

    Winston-Salem, North Carolina, 27104, United States

  • Washington University in St. Louis

    St Louis, Missouri, 63110, United States

  • Weill Cornell

    New York, New York, 10021, United States

  • Yale University

    Fairfield, Connecticut, 06824, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.